Sarepta Therapeutics (SRPT) to Announce Quarterly Earnings on Wednesday

Sarepta Therapeutics (NASDAQ:SRPT) is anticipated to post its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Sarepta Therapeutics to post earnings of $0.4861 per share and revenue of $381.9780 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $2.18. The company had revenue of $730.80 million for the quarter, compared to the consensus estimate of $474.15 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The company’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period last year, the business posted ($3.42) EPS. On average, analysts expect Sarepta Therapeutics to post $4 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $15.43 on Wednesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62. Sarepta Therapeutics has a 1-year low of $14.68 and a 1-year high of $25.32. The firm has a market capitalization of $1.63 billion, a P/E ratio of -16.07, a P/E/G ratio of 0.17 and a beta of 0.21. The business’s 50-day simple moving average is $17.09 and its 200-day simple moving average is $18.83.

Analyst Ratings Changes

Several research analysts recently commented on SRPT shares. Weiss Ratings upgraded shares of Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, July 20th. Wolfe Research upgraded shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research note on Thursday, July 9th. Royal Bank Of Canada increased their price objective on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the stock a “sector perform” rating in a research report on Tuesday, April 7th. Wall Street Zen raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, July 4th. Finally, Zacks Research lowered shares of Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 7th. Nine equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and six have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $24.72.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC purchased a new position in Sarepta Therapeutics in the 4th quarter worth approximately $25,000. iSAM Funds UK Ltd purchased a new stake in shares of Sarepta Therapeutics during the third quarter valued at approximately $25,000. Ancora Advisors LLC raised its stake in shares of Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,000 shares during the period. Allworth Financial LP lifted its position in shares of Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,721 shares in the last quarter. Finally, Parallel Advisors LLC lifted its position in shares of Sarepta Therapeutics by 165.3% during the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 1,256 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.